Holen Sie sich die Stockscreener-App
3.55
1.43%
0.05
Handel nachbörslich:
3.54
-0.010
-0.28%
Schlusskurs vom Vortag:
$3.50
Offen:
$3.46
24-Stunden-Volumen:
345.98K
Relative Volume:
0.72
Marktkapitalisierung:
$108.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.25M
KGV:
-2.9933
EPS:
-1.186
Netto-Cashflow:
$-22.80M
1W Leistung:
+2.90%
1M Leistung:
+3.80%
6M Leistung:
-37.61%
1J Leistung:
-34.26%
1-Tages-Spanne:
$3.32
$3.63
1-Wochen-Bereich:
$3.32
$3.85
52-Wochen-Spanne:
$1.73
$7.38
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Vergleichen Sie SGMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
3.55 | 111.07M | 0 | -29.25M | -22.80M | -1.186 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment - Investing.com Australia
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment By Investing.com - Investing.com Nigeria
Sagimet Biosciences to host KOL event on denifanstat, resmetirom - TipRanks
Sagimet Biosciences (SGMT) to Host Key Opinion Leader Event on I - GuruFocus
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating - GlobeNewswire
Leading MASH Expert to Present Groundbreaking Denifanstat-Resmetirom Combination Therapy Data - Stock Titan
Dimensional Fund Advisors LP Buys Shares of 25,334 Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
6,810 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Bought by Wells Fargo & Company MN - Defense World
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Wednesday - Defense World
Sagimet Biosciences Reports Q1 2025 Financial Results - MSN
Sagimet Biosciences, Inc.: A Promising Investment in the NASH Market with Strategic Growth Initiatives - TipRanks
Oppenheimer Revises Price Target for Sagimet Biosciences (SGMT) - GuruFocus
Oppenheimer Revises Price Target for Sagimet Biosciences (SGMT) | SGMT Stock News - GuruFocus
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Sagimet Biosciences Reports Q1 Financial Results and Updates - TipRanks
Renaissance Technologies LLC Sells 220,300 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc (SGMT) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Take off with Sagimet Biosciences Inc (SGMT): Get ready for trading - Sete News
Sagimet Biosciences announces board change - Investing.com Australia
Geode Capital Management LLC Increases Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences announces board change By Investing.com - Investing.com Nigeria
Sagimet Biosciences Inc [SGMT] Investment Appeal on the Rise - knoxdaily.com
Sagimet Biosciences Inc (SGMT)’s stock chart: A technical perspective - uspostnews.com
Insider’s View: Deciphering Sagimet Biosciences Inc (SGMT)’s Financial Health Through Ratios - DWinneX
Sagimet Biosciences Inc [SGMT] Shares Rise 8.82 % on Wednesday - knoxdaily.com
What is Sagimet Biosciences Inc (SGMT) Stock Return on Shareholders’ Capital? - Sete News
Sagimet Biosciences (SGMT) to Present Denifanstat Study Findings at EASL 2025 | SGMT Stock News - GuruFocus
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025 - GlobeNewswire
Breakthrough MASH Drug Shows Extended Phase 2b Results: 3 New Analyses Reveal Treatment Impact - Stock Titan
Sagimet Biosciences Inc (SGMT) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Predicting Sagimet Biosciences Inc’s (SGMT) earnings for the current quarter - uspostnews.com
SGMT’s Stock Market Adventure: -51.78% YTD Growth Amidst Volatility - investchronicle.com
20,103 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by American Century Companies Inc. - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Holdings of Sagimet Biosciences Inc (SGMT) are aligned with the stars - Sete News
SGMT’s Debt-to-Equity Ratio at 0.00: What It Means for Sagimet Biosciences Inc’s Future - investchronicle.com
Virtu Financial LLC Sells 9,123 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - The AM Reporter
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Consensus Price Target from Analysts - Defense World
HC Wainwright Issues Positive Estimate for SGMT Earnings - Defense World
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday - Defense World
Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position - TipRanks
HC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom - TipRanks
Sagimet Biosciences Advances MASH Treatment with New Trials - TipRanks
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet’s FASN inhibitor cleared to enter clinic for acne - BioWorld MedTech
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):